Review how trial sponsors are obtaining a clearer understanding of how a drug is performing against safety and efficacy endpoints while the study is underway, without increasing alpha-spend. Discover how unified insight into live data helped one biopharmaceutical company achieve the industry’s first-ever successful New Drug Application (NDA) in a highly challenging indication.
Held February 24, 2022
Register: Prevail Xtalks Webinar